Ginkgo Bioworks Holdings, Inc. (DNA )

Currency in USD Disclaimer
$15.08 +$0.79 (5.51%)
Open 02/05/2025
$13.98
$15.08
$5.26
$64.4

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol DNA
  • Company Ginkgo Bioworks Holdings, Inc.
  • Price $15.08
  • Changes Percentage 5.51
  • Change 0.7872
  • Day Low $13.98
  • Day High $15.08
  • Year High $64.4
  • Year Low $5.26
  • Market Cap $845,802,131
  • Price Avg 50 EMA (D) $10.15
  • Price Avg 200 EMA (D) $14
  • Exchange NYSE
  • Volume 300,421
  • Average Volume 1,410,322
  • Open $14.47
  • Previous Close $14.29
  • EPS -12.4
  • PE -1.19
  • Earnings Announcement 2025-02-27 12:00:00
  • Shares Outstanding $57,478,908

Company brief: GINKGO BIOWORKS HOLDINGS, INC. (DNA )

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

DNA Corporation News

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

February 5, 2025 at 1:00 pm ET

globenewswire.com -- DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatm...

Income Statement